Takeover Rumors Surround Endo Health Solutions Inc (ENDP)

Endo Health Solutions Inc (NASDAQ:ENDP) shares popped more than 17% last week on rumors of exploratory talks with potential buyers including Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Warner Chilcott Plc (NASDAQ:WCRX). This week, Bloomberg reported that the push to sell might come from Fidelity Investments — Endo’s largest shareholder.

It’s best to take sale rumors with a bag of salt. But here’s a look back at the tough year that left Endo in a more vulnerable position.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX)String of bad news
Branded pharmaceuticals made up the majority of Endo’s revenues last year. In the third quarter, the pain patch Lidoderm accounted for 32% of overall revenues and over half of its segment. The bad news? Lidoderm’s patent expired last fall. An expensive patent battle with Actavis Inc (NYSE:ACT), formerly Watson, delayed the generic release but only until this September .

Opana ER earned the second slot in the branded drug department, accounting for 8% of overall revenues that quarter following a 36% slip due to a supply issue. Endo replaced the original formula with a crush-resistant formulation that’s harder to abuse. The company later sued the FDA  to try and prevent generic alternatives from entering the market, claiming that their non-tamper-resistant nature posed a safety risk to patients. But a court dismissed the case and opened the path for generics.

In December, Endo announced that CEO David P. Holveck plans to step down this spring, and a search for a replacement is still under way. The company used the same press release to lower its 2013 forecast to include EPS of $4.40 to $4.70 per share and revenues of $2.80 billion to $2.95 billion. That’s down from the month-prior prediction with an EPS of $5.20 to $5.40 per share and revenues of $3 to $3.02 billion.

Bright spot
Endo has more happening than Lidoderm and Opana ER. The generic drug subsidiary Qualitest held 22% of overall revenues in the third quarter and future growth here could offset a bit of the losses from pharmaceuticals. Qualitest launched a generic for Merck & Co., Inc. (NYSE:MRK)‘s asthma medication Singulair last summer and later received FDA approvals for generic versions of Avapro and Provigil. The generics market tends to be competitive with low margins.

The article Takeover Rumors Surround This Drug Stock originally appeared on Fool.com and is written by Brandy Betz.

Fool contributor Brandy Betz has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!